Login

Join for Free!
114461 members
table of contents table of contents

A fully automated assay to determine the enzymology of drug oxidation by …


Biology Articles » Biochemistry » Enzymology » Automated Definition of the Enzymology of Drug Oxidation by the Major Human Drug Metabolizing Cytochrome P450s » References

References
- Automated Definition of the Enzymology of Drug Oxidation by the Major Human Drug Metabolizing Cytochrome P450s


  • Andersson T, Miners JO, Veronese ME and Birkett DJ (1994) Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol  38: 131-137.
  • Andersson T, Miners JO, Veronese ME, Tassaneeyakul W, Tassaneeyakul W, Meyer UA and Birkett DJ (1993) Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol  36: 521-530 
  • Aoyama T, Korzekwa K, Nagata K, Gillette J, Gelboin HV and Gonzalez FJ (1990) Estradiol metabolism by complementary deoxyribonucleic acid-expressed human cytochrome P450s. Endocrinology  126: 3101-3106
  • Ayrton J, Plumb R, Leavens WJ, Mallett D, Dickins M and Dear GJ (1998) Application of a generic fast gradient liquid chromatography tandem mass spectrometry method for the analysis of cytochrome P450 probe substrates. Rapid Commun Mass Spectrom  12: 217-224
  • Back DJ, Tjia JF, Karbwang J and Colbert J (1988) In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. Br J Clin Pharmacol  26: 23-29
  • Becquemont L, Le Bot MA, Riche C, Funck-Brentano C, Jaillon P and Beaune P (1998) Use of heterologously expressed human cytochrome P450 1A2 to predict tacrine-fluvoxamine drug interaction in man. Pharmacogenetics  8: 101-108
  • Belloc C, Baird S, Cosme J, Lecoeur S, Gautier JC, Challine D, de Waziers I, Flinois JP and Beaune PH (1996) Human cytochromes P450 expressed in Escherichia coli: production of specific antibodies. Toxicology  106: 207-219
  • Bertz RJ and Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet  32: 210-258
  • Boobis AR, Mckillop D, Robinson DT, Adams DA and McCormick DJ (1998) Interlaboratory comparison of the assessment of P450 activities in human hepatic microsomal samples. Xenobiotica  28: 493-506
  • Bourrie M, Meunier V, Berger Y and Fabre G (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther  277: 321-332
  • Broly F, Libersa C, Lhermitte M and Dupuis B (1990) Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomes. Biochem Pharmacol  39: 1045-1053
  • Carlile DJ, Hakooz N, Bayliss MK and Houston JB (1999) Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. Br J Clin Pharmacol  47: 625-635
  • Chauret N, Gauthier A and Nicoll-Griffith DA (1998) Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos  26: 1-4
  • Crespi CL, Miller VP and Penman BW (1998) High throughput screening for inhibition of cytochrome P450 metabolism. Med Chem Res  8: 457-471.
  • Dayer P, Leemann T and Striberni R (1989) Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 db1 activity. Clin Pharmacol Ther  45: 34-40
  • Doecke CJ, Veronese ME, Pond SM, Miners JO, Birkett DJ, Sansom LN and McManus ME (1991) Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br J Clin Pharmacol  31: 125-130
  • Eddershaw PJ and Dickins M (1999) Advances in in vitro drug metabolism screening. Pharm Sci Technol Today  2: 13-19
  • Fischer V, Johanson L, Heitz F, Tullman R, Graham E, Baldeck JP and Robinson WT (1999) The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: Effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Dispos  27: 410-416
  • Guengerich FP and Turvy CG (1991) Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharmacol Exp Ther  256: 1189-1194
  • Hamman MA, Thompson GA and Hall SD (1997) Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem Pharmacol  54: 33-41
  • Hickman D, Wang J-P, Wang Y and Unadkat JD (1998) Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab Dispos  26: 207-215
  • Houston JB (1994) Relevance of in vitro kinetic parameters to in vivo metabolism of xenobiotics. Toxicol in Vitro  8: 507-512.
  • Imaoka S, Yamada T, Jiroi T, Hayashi K, Sakaki T, Yabusaki Y and Funae Y (1996) Multiple forms of human P450 expressed in Saccharomyces cerevisiae: Systematic characterization and comparison with those of the rat. Biochem Pharmacol  51: 1041-1050
  • Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP and Shimada T (1997) Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics  7: 103-113
  • Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA and Sugiyama Y (1997) Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther  73: 5147-5171.
  • Jacqz-Aigrain E, Funck-Brentano C and Cresteil T (1993) CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics  3: 197-204
  • Jung F, Richardson TH, Raucy JL and Johnson EF (1997) 0 Diazepam metabolism by cDNA-expressed human 2C P450s: Identification of P4502C18 and P4502C19 as low Km diazepam N-demethylases. Drug Metab Dispos  25: 133-139
  • Karam WG, Goldstein JA, Lasker JM and Ghanayem BI (1996) 0 Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab Dispos  24: 1081-1087
  • Kerry NL, Somogyi AA, Bochner F and Mikus G (1994) 0 The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: In vitro studies using human liver microsomes. Br J Clin Pharmacol  38: 243-248
  • Kobayashi K, Chiba K, Tani M, Kuroiwa Y and Ishizaki T (1994) Development and preliminary application of a high-performance liquid chromatographic assay for omeprazole metabolism in human liver microsomes. J Pharm Biomed Anal  12: 839-844
  • Kroemer HK, Gautier JC, Beaune P, Henderson C, Wolf CR and Eichelbaum M (1993) Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn-Schmiedeberg's Arch Pharmacol  348: 332-337
  • Lasker JM, Wester MR, Aramsombatdee E and Raucy JL (1998) 0 Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch Biochem Biophys  353: 16-28
  • Leemann TD, Transon C, Bonnabry P and Dayer P (1993) A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal anti-inflammatory drugs. Drugs Exp Clin Res  19: 189-195
  • Lennard MS, Jackson PR, Freestone S, Tucker GT, Ramsay LE and Woods HF (1984) The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol. Br J Clin Pharmacol  17: 679-685
  • Machinist JM, Mayer MD, Roberts EM, Surber BW and Rodrigues AD (1998) Identification of the human liver cytochrome P450 enzymes involved in the in vitro metabolism of a novel 5-lipoxygenase inhibitor. Drug Metab Dispos  26: 970-976
  • Mautz DS, Nelson WL and Shen DD (1995) Regioselective and stereoselective oxidation of metoprolol and bufuralol catalyzed by microsomes containing cDNA-expressed human P4502D6. Drug Metab Dispos  23: 513-517
  • McGinnity DF, Griffin SJ, Moody GC, Voice M, Hanlon S, Friedberg T and Riley RJ (1999) Rapid characterization of the major drug-metabolizing human hepatic cytochrome P-450 enzymes expressed in Escherichia coli. Drug Metab Dispos  27: 1017-1023
  • Moody GC, Griffin SJ, Mather AN, McGinnity DF and Riley RJ (1999) Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: Assessment of human CYP inhibition potential. Xenobiotica  29: 53-75
  • Nakajima M, Nakamura S, Tokudome S, Shimada N, Yamazaki H and Yokoi T (1999) Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos  27: 1381-1391
  • Obach RS (1997) Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab Dispos  25: 1359-1369
  • Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos  27: 1350-1359
  • Omura T and Sato R (1964) 0 The carbon monoxide-binding pigment of liver microsomes I. Evidence for its hemoprotein nature. J Biol Chem  239: 2370-2378
  • Ono S, Hatanaka T, Miyazawa S, Tsutsui M, Aoyama T, Gonzalez FJ and Satoh T (1996) Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: Role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica  26: 1155-1166
  • Otton SV, Crewe HK, Lennard MS, Tucker GT and Woods HF (1988) Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther  247: 242-247
  • Otton SV, Gillam EMJ, Lennard MS, Tucker GT and Woods HF (1990) Propranolol oxidation by human liver microsomes: The use of cumene hydroperoxide to probe isoenzyme specificity and regio- and stereoselectivity. Br J Clin Pharmacol  30: 751-760
  • Pichard L, Gillet G, Fabre I, Dalet-Beluche I, Bonfils G, Thenot JP and Maurel P (1990) Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem. Drug Metab Dispos  18: 711-719
  • Rodrigues AD (1994) Use of in vitro human metabolism studies in drug development: An industrial perspective. Biochem Pharmacol  48: 2147-2156
  • Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping: Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol  57: 465-480
  • Rodrigues AD, Kukulka MJ, Surber BW, Thomas SB, Uchic JT, Rotert GA, Michel G, Thome-Kromer B and Machinist JM (1994) Measurement of liver microsomal cytochrome p450 (CYP2D6) activity using [O-methyl-14C]dextromethorphan. Anal Biochem  219: 309-320
  • Roy P, Yu LJ, Crespi CL and Waxman DJ (1999) Development of a substrate-activity based approach to identify the major human liver P-450 catalyts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos  27: 655-666
  • Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP (1994) 0 Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther  270: 414-423
  • Sutton D, Butler AM, Nadin L and Murray M (1997) Role of CYP3A4 in human hepatic diltiazem N-demethylation: Inhibition of CYP3A4 activity by oxidized diltiazem metabolites. J Pharmacol Exp Ther  282: 294-300
  • Tassaneeyakul W, Mohamed Z, Birkett DJ, McManus ME, Veronese ME, Tukey RH, Quattrochi LC, Gonzalez FJ and Miners JO (1992) Caffeine as a probe for human cytochromes P450: Validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics  2: 173-183
  • Tracy TS, Korzekwa KR, Gonzalez FJ and Wainer IW (1999) Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br J Clin Pharmacol  47: 545-552
  • Venkatakrishnan K, Von Moltke LL and Greenblatt DJ (1998) Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: Application of the relative activity factor approach. J Pharm Sci  87: 845-853
  • Venkatakrishnan K, Von Moltke LL, Obach RS and Greenblatt DJ (2000) Microsomal binding of amitriptyline: Effect on estimation of enzyme kinetic parameters in vitro. J Pharmacol Exp Ther  293: 343-350
  • Von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Venkatakrishnan K, Schmider J, Harmatz JS and Shader RI (1998) Multiple human cytochromes contribute to biotransformation of dextromethorphan in vitro: Role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. J Pharm Pharmacol  50: 997-1004
  • Wang RW, Newton DJ, Scheri TD and Lu AYH (1997) Human cytochrome P450 3A4-catalyzed testosterone 6beta-hydroxylation and erythromycin N-demethylation: Competition during catalysis. Drug Metab Dispos  25: 502-507
  • Watanabe N, Kamei S, Ohkubo A, Yamanaka M, Ohsawa S, Makino K and Tokuda K (1986) Urinary protein as measured with a pyrogallol red-molybdate complex, manually and in a Hitachi 726 automated analyzer. Clin Chem  32: 1551-1554
  • Waxman DJ, Attisano C, Guengerich FP and Lapenson DP (1988) Human liver microsomal steroid metabolism: Identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme. Arch Biochem Biophys  263: 424-436
  • Wester MR, Lasker JM, Johnson EF and Raucy JL (2000) CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes. Drug Metab Dispos  28: 354-359
  • Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP and Shimada T (1997) Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: Effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther  283: 434-442
  • Yamazaki H, Nakajima M, Nakamura M, Asahi S, Shimada N, Gillam EMJ, Guengerich FP, Shimada T and Yokoi T (1999) Enhancement of cytochrome P-450 3A4 catalytic activities by cytochrome b5 in bacterial membranes. Drug Metab Dispos  27: 999-1004
  • Yasumori T, Nagata K, Yang SK, Chen LS, Murayama N, Yamazoe Y and Kato R (1993) Cytochrome P450-mediated metabolism of diazepam in humans and rats: Involvement of human CYP2C in N-demethylation in a substrate concentration-dependent manner. Pharmacogenetics  3: 291-301
  • Yoshimoto K, Echizen H, Chiba K, Tani M and Ishizaki T (1995) Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers-N-desisopropylation is mediated mainly by CYP1A2. Br J Clin Pharmacol  39: 421-431

rating: 0.00 from 0 votes | updated on: 7 Feb 2009 | views: 6328 |

Rate article:







excellent!bad…